Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Postimmunotherapy lineage switch: where to from here?

24 Jul 2025

Abstract excerpt

grade ≥2 CRS was significantly reduced in the itacitinib group (17.4%) compared with placebo (56.4%).Itacitinib use was associated with reduced tocilizumab use.Dexamethasone use was low overall, with 3 patients receiving steroids in the placebo group and none in the group given itacitinib 200 mg twice daily.Rates of ICANS were numerically lower in the prophylactic itacitinib-treated group as well.Given the broad...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40705391
DOI: 10.1182/blood.2025029260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postimmunotherapy lineage switch: where to from here?PMID 40705391Read ↗

Pre-infusion plasma proteomics identifies an endothelial–immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphomaSemantic proximity Read ↗

Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world settingSemantic proximity Read ↗

Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Semantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysSemantic proximity Read ↗

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSemantic proximity Read ↗

Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity Read ↗

The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management.Semantic proximity Read ↗

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in SwedenSemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.